Back

Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy in HELIOS-B who had progressed on tafamidis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Jose Gonzalez-Costello

Bellvitge University Hospital, Hospitalet De Llobregat (Spain)

6 More presentations in this session

Presentation thumbnail
Implementation of sodium-glucose co-transporter 2 inhibitors use in patients with heart failure across the ejection fraction: data from the Swedish heart failure registry
Doctor G. Ferrannini (Stockholm, SE)
Abstract Slides Video
Presentation thumbnail
Acoramidis improves serum TTR levels in patients with wild-type or variant transthyretin amyloid cardiomyopathy - results from ATTRibute-CM
Doctor A. Ducharme (Montreal, CA)
Abstract Slides Video
Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Metabolic effects of 14-day oral ketone ester treatment in patients with heart failure with reduced ejection fraction
Mr K. Berg-Hansen (Aarhus, DK)
Abstract Slides Video
Presentation thumbnail
Outcome and disease progression in patients with wild-type transthyretin cardiomyopathy treated with tafamidis
Associate Professor A. Cipriani (Padua, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Evolving treatment paradigms in heart failure: from SGLT2 inhibition to transthyretin stabilisation and beyond
Video

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
HELIOS-B: 12-month results from the open-label extension period of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
thumbnail
Congress Session
Advances in amyloidosis
thumbnail
Congress Presentation
HELIOS-B: Vutrisiran reduces all-cause mortality

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources